<DOC>
	<DOCNO>NCT02232477</DOCNO>
	<brief_summary>This five-year extension study pilot study , `` Intrathecal Enzyme Replacement Cognitive Decline MPS I '' . Participants must complete pilot study participate study .</brief_summary>
	<brief_title>Extension Study Intrathecal Enzyme Replacement Cognitive Decline MPS I</brief_title>
	<detailed_description />
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mucopolysaccharidosis I</mesh_term>
	<criteria>1 . The subject complete MIRC002 study intrathecal enzyme replacement therapy cognitive decline mucopolysaccharidosis I 2 . Age six year old . 3 . Subject and/or guardian willing able provide write informed consent . 4 . Negative urine pregnancy test screening ( nonsterile female childbearing potential ) 5 . Currently use two acceptable method birth control determine investigator willing continue use acceptable birth control participation study ( nonsterile female childbearing potential sexually active ) 6 . Willing able comply study procedure . For example , subject must able complete write computerbased testing . The subject must able lie still MRI scanner least 40 minute without sedation . 1 . The subject undergone hematopoietic stem cell transplantation 2 . Recent initiation intravenous Aldurazyme® therapy le 6 month therapy . Subjects receive Aldurazyme® therapy 6 month , never receive Aldurazyme® therapy , allow enroll 3 . Pregnant lactating , consider pregnancy 4 . Receipt investigational drug procedure intrathecal Aldurazyme® within 30 day enrollment 5 . A condition , medical , prevents participation study , include severe auditory visual impairment , significant lumbar pathology , lumbar catheter , recent major surgery within 6 week would preclude ability participate . 6 . Infusion reaction intravenous intrathecal Aldurazyme® therapy lifethreatening require emergent intervention epinephrine , cardiopulmonary resuscitation , hospitalization 7 . The subject severely impaired spinal CSF flow , demonstrated failure appearance radionuclide basal cisterns 4 hour intralumbar administration . 8 . The subject coagulopathy , identify platelet count less 50,000 , INR 1.5 great , PTT 1.5 time upper limit normal laboratory drawn .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>